Intravenous immunoglobulin (IVIg) infusions at 3–4 week intervals are currently standard therapy in the United States for patients with primary immune deficiency diseases (PIDD). To evaluate alternative modes of immunoglobulin administration we have designed an open-label study to investigate the efficacy and safety of a subcutaneously administered immunoglobulin preparation (16% IgG) in patients with PIDD. After their final IVIg infusion, 65 patients entered a 3-month, wash-in/wash-out phase, designed to bring patients to steady-state with subcutaneously administered immunoglobulin. This was followed by 12 months of weekly SCIg infusions, at a dose determined in a pharmacokinetic substudy to provide noninferior intravascular exposure. This resulted in a mean weekly dose of 158 mg/kg, calculated to equal 137% of the previous intravenous dose. Two patients (4%) each reported 1 serious bacterial infection (pneumonia), an annual rate of 0.04 per patient-year. There were 4.43 infections of any type per patient-year. Mean trough serum IgG levels increased from 786 to 1040 mg/dL during the study, a mean increase of 39%. The most frequent treatment-related adverse event was infusion-site reaction, reported by 91% of patients; this was predominantly mild or moderate, and the incidence decreased over time. No treatment-related serious adverse events were reported. We conclude that subcutaneous administration of 16% SCIg is a safe and effective alternative to IVIg for replacement therapy of PIDD.
Similar content being viewed by others
Abbreviations
- AEs:
-
adverse events
- CL:
-
confidence limit
- HIV:
-
human immunodeficiency virus
- ITT:
-
intention-to-treat
- IgA:
-
immunoglobulin A
- IgG:
-
immunoglobulin G
- PIDD:
-
primary immune deficiency diseases
- IVIg:
-
intravenously administered immunoglobulin
- SCIg:
-
subcutaneously administered immunoglobulin
- SBIs:
-
serious bacterial infections.
REFERENCES
Bruton OC: Agammaglobulinemia. Pediatrics 9:722–728, 1952.
Björkander J, Chapel H, Spickett G: Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous immunoglobulin in the prevention of infection in patients with primary antibody deficiency syndromes. Mol Immunol 35:11–12, 1998.
Cunningham-Rundles C, Siegel F, Smithwick E, Lion-Boule A, Cunningham-Rundles S, O’Malley J: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101:435–439, 1984.
Lederman H, Roifman C, Lavi S, Gelfand E: Corticosteroids for prevention of adverse reactions to intravenous immune globulin infusions, in hypogammaglobulinemic patients. Am J Med 81:443–446, 1986.
Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 273:1865–1870, 1995.
Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH: Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 19:388–391, 1996.
Brannagan TH, 3rd, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47:674–677, 1996.
Immune Deficiency Foundation 2003, posting date. Treatment experiences and preferences of patients with primary immune deficiency disease: First national survey. [Online.]
Berger M, Cupps TR, Fauci AS: Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93:55–56, 1980
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94–100, 2000.
Gardulf A, Hammarstrom L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162–166, 1991
Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI: The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 92:200–204, 1993.
Gardulf A, Hammarstrom L: Subcutaneous administration of immunoglobulins: What are the advantages? Clin Immunother 6:108–116, 1996.
Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G, et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 345:365–369, 1995.
Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, Costa-Carvalho BT, Granert C, Haag S, Hernandez D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M: Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114:936–942, 2004.
Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD: Health-related quality of life and treatment satisfaction in north american patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26:65–72, 2006.
Ochs HD, Pinciaro PJ: Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24:309–314, 2004.
Berger M: Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112:1–7, 2004.
Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165–174, 2001.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, et al.: Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol In press, 2006.
Pruzanski W, Sussman G, Dorian W, Van T, Ibanez D, Redelmeier D: Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 20:353–359, 1996.
Gaspar J, Gerritsen B, Jones A: Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79:48–51, 1998.
Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314:560–564, 1986.
Sundin U, Nava S, Hammarstrom L: Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglo-bulin infusion therapy. Clin Exp Immunol 112:341–346, 1998.
Eijkhout HW, van den Broek PJ, van der Meer JW: Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 61:213–217, 2003.
Berger M, Pinciaro PJ: Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389–396, 2004.
Ochs HD, Fischer SH, Wedgwood RJ, Wara DW, Cowan MJ, Ammann AJ, Saxon A, Budinger MD, Allred RU, Rousell RH: Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 76:78–82, 1984.
Stiehm ER: Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 16:696–707, 1997.
ACKNOWLEDGMENTS
The clinical investigation was sponsored by ZLB Behring, Marburg, Germany. Dr Kiessling is employed by ZLB Behring; Dr Berger has received research support and consulting fees from ZLB Behring. We thank all of the personnel involved in this investigation.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Ochs, H.D., Gupta, S., Kiessling, P. et al. Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases. J Clin Immunol 26, 265–273 (2006). https://doi.org/10.1007/s10875-006-9021-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-006-9021-7